Provided by HepCBC
On August 22nd, 2013 the Canadian Agency for Drugs and Technologies in Health (CADTH) released a call for patient input into Janssen Inc.’s new HCV drug, SIMEPREVIR. In order to prepare our Patient Group submission by the Sept. 13th deadline, HepCBC is ASKING for INPUT from HCV+ people and caregivers from throughout Canada, by Wednesday, Sept. 11th. CLICK HERE to ADD YOUR VOICE in determining whether this new treatment should be available in Canada, by contributing your ideas and experiences to HepCBC’s group submission.
No comments:
Post a Comment